GLSHQ (Gelesis Holdings) Other Financing: $0.05 Mil (TTM As of Jun. 2023)


What is Gelesis Holdings Other Financing?

Gelesis Holdings GLSHQ -99.00% Other Financing is $0.05 Mil as of Jun. 2023.

Gelesis Holdings's Other Financing for the three months ended in Jun. 2023 was $0.00 Mil.

Gelesis Holdings's Other Financing for the trailing twelve months (TTM) ended in Jun. 2023 was $0.05 Mil.

Gelesis Holdings Other Financing Historical Data

* Premium members only.

The historical data trend for Gelesis Holdings's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gelesis Holdings Other Financing Chart

Gelesis Holdings Annual Data
Trend Dec21 Dec22
Other Financing
0.16 70.60

Gelesis Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.04 0.01 0.00 0.00

Gelesis Holdings Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $0.05 Mil mean?
Gelesis Holdings (GLSHQ) has a Other Financing of $0.05 Mil as of Jun. 2023. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Gelesis Holdings and its competitors.
Is Gelesis Holdings' Other Financing too high?
Gelesis Holdings' current Other Financing is $0.05 Mil.
How does Gelesis Holdings' Other Financing compare to RBSH and PPCB?
Gelesis Holdings' Other Financing of $0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Gelesis Holdings and its competitors. Gelesis Holdings's current Other Financing is $0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelesis Holdings stock overvalued right now?
Gelesis Holdings (GLSHQ) has a current Other Financing of $0.05 Mil. The current Other Financing is $0.05 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Gelesis Holdings (GLSHQ), the current Other Financing is $0.05 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gelesis Holdings Business Description

Address 501 Boylston Street, Suite 6102, Boston, MA, USA, 02116
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.